.png)
Eyes On Regulatory Momentum: FDA Decisions Shape Oncology and Vaccine Markets
- Jana Chisholm
- 35 minutes ago
- 3 min read
This week we had Eyes On recent FDA actions including the approval of AstraZeneca’s first fixed-duration BTK inhibitor regimen for first-line CLL/SLL; A warning letter for Johnson & Johnson concerning promotional claims for Tremfya; and Moderna's resolution of the refusal-to-file dispute and a PDUFA for it's flu vaccine decision in 2026.
AstraZeneca Wins Key Approval in the BTK Inhibitor Market
The FDA has approved a combination of Calquence (acalabrutinib) and Venclexta (venetoclax) as the first all-oral, fixed-duration regimen for first-line treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The approval marks an important regulatory milestone for AstraZeneca, which has been working to reclaim leadership in the BTK inhibitor market. Unlike standard BTK therapies that are taken indefinitely until disease progression, the newly approved regimen is limited to 14 months of treatment, offering patients a defined therapy duration and giving physicians greater flexibility in treatment sequencing.
Phase 3 Data Behind the Approval
The decision was supported by the AMPLIFY phase 3 trial, where the Calquence-Venclexta combination demonstrated strong efficacy compared with investigator-choice chemoimmunotherapy.
Key findings included:
35% reduction in risk of disease progression or death
Median progression-free survival:
Control arm: 47.6 months
Calquence combination: Not yet reached
Overall survival:
6% mortality in the Calquence-Venclexta arm
14% mortality in the comparator arm
Median follow-up: 41 months
Investigators described the combination as well tolerated and potentially practice-changing for first-line CLL treatment. However, competitors remain skeptical.
BeOne Medicines, which markets Brukinsa (zanubrutinib), argued that cross-trial comparisons suggest inferior minimal residual disease (MRD) outcomes compared with AbbVie’s fixed-duration Venclexta-Gazyva regimen. The company also pointed to a late acceleration of progression events in the Calquence arm of the study.
Despite the debate, AstraZeneca believes the time-limited regimen will appeal to clinicians seeking alternatives to lifelong BTK therapy.
FDA Challenges Johnson & Johnson’s Tremfya Advertising
The FDA also issued an untitled letter to Johnson & Johnson regarding television advertisements for Tremfya (guselkumab) in ulcerative colitis. Unlike many recent promotional warnings, the agency did not focus on visual presentation. Instead, it challenged the interpretation of clinical trial data used to support claims in the commercial.
The advertisement stated that:
· “1 in 2 patients” achieved clinical remission at one and two years
· About one-third of patients achieved endoscopic remission
According to the FDA, those claims were based on maintenance-trial data from a subset of patients who had already responded to Tremfya during induction therapy.
The agency concluded the messaging overstated the drug’s efficacy.
The letter also criticized a claim that the drug could “heal” intestinal tissue, stating that endoscopic response does not necessarily predict long-term clinical outcomes.
Johnson & Johnson has 15 working days to respond.
Moderna Resolves Flu Vaccine Filing Dispute
Regulatory tensions eased for Moderna after the FDA accepted an updated submission for its mRNA-1010 influenza vaccine, reversing an earlier refusal-to-file decision.
The initial rejection stemmed from concerns that the control arm in the phase 3 trial did not represent the best available standard of care.
Following discussions with regulators, Moderna submitted a revised filing that splits the approval pathway by age group:
Accelerated approval request: adults 65+
Full approval request: adults 50–64
The FDA decision is expected by August 5, positioning the vaccine for potential launch ahead of the 2026–2027 flu season.
In premarket trading following the news, Moderna shares rose 7% to $47.
